{"id":"sofosbuvir-simeprevir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Anemia"},{"rate":"5-10","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL3137358","moleculeType":"Small molecule","molecularWeight":"771.94"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Simeprevir is a protease inhibitor that blocks the NS3/4A serine protease, which is essential for viral polyprotein processing. Together, they provide dual inhibition of critical viral enzymes needed for HCV replication.","oneSentence":"Sofosbuvir and simeprevir work together to inhibit hepatitis C virus replication by blocking the NS5B polymerase and NS3 protease, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:41.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1-6)"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02262728","phase":"PHASE2","title":"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-30","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT03882307","phase":"EARLY_PHASE1","title":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT02455167","phase":"PHASE3","title":"Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-05","conditions":"Hepatitis C","enrollment":9},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT04385407","phase":"PHASE2","title":"Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-04","conditions":"Chronic Hepatitis C Virus Infection","enrollment":203},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT02206932","phase":"PHASE4","title":"A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2014-08","conditions":"Hepatitis C, Chronic, HIV CDC Category A1","enrollment":""},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Antiviral Drug","enrollment":80},{"nctId":"NCT02421211","phase":"PHASE2","title":"A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-05-19","conditions":"Hepatitis C, Chronic","enrollment":41},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT02214420","phase":"PHASE4","title":"SMV + SOF With/Without RBV for IFN-II Patients With CHC","status":"COMPLETED","sponsor":"SC Liver Research Consortium, LLC","startDate":"2014-10","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT02628717","phase":"","title":"Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-07","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":558},{"nctId":"NCT02624063","phase":"PHASE4","title":"Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT02932293","phase":"PHASE2","title":"Triple Combination DAAs for Treating HCV GT1b Subjects","status":"WITHDRAWN","sponsor":"Humanity and Health Research Centre","startDate":"2016-12","conditions":"Chronic Hepatitis C Infection","enrollment":""},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":"Hepatitis C, Chronic, Hemoglobinopathies","enrollment":168},{"nctId":"NCT03133065","phase":"PHASE4","title":"Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09","conditions":"Liver Transplantation","enrollment":89},{"nctId":"NCT03069001","phase":"PHASE4","title":"Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-06","conditions":"HCV","enrollment":90},{"nctId":"NCT02349048","phase":"PHASE2","title":"Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"Hepatitis C Virus","enrollment":68},{"nctId":"NCT02250807","phase":"PHASE3","title":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-01","conditions":"Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02165189","phase":"PHASE2","title":"An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2014-08","conditions":"Hepatitits C","enrollment":46},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02278419","phase":"PHASE2","title":"An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2014-12","conditions":"Hepatitis C","enrollment":63},{"nctId":"NCT02485080","phase":"PHASE4","title":"Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2015-09","conditions":"PT-NANBH","enrollment":""},{"nctId":"NCT02771405","phase":"PHASE3","title":"Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02531269","phase":"","title":"Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03","conditions":"Hepatitis C","enrollment":249},{"nctId":"NCT02114177","phase":"PHASE3","title":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":310},{"nctId":"NCT02114151","phase":"PHASE3","title":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":103},{"nctId":"NCT02168361","phase":"PHASE4","title":"The SIM-SOF Trial for Hepatitis C","status":"COMPLETED","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2013-12","conditions":"Chronic Hepatitis C","enrollment":93},{"nctId":"NCT02702739","phase":"PHASE4","title":"Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Camillo Forlanini","startDate":"2015-01","conditions":"Liver Cirrhosis","enrollment":270},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02253550","phase":"PHASE2","title":"Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Peter J. Ruane, M.D.","startDate":"2014-10","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT02485262","phase":"","title":"Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience","status":"UNKNOWN","sponsor":"Arrowhead Regional Medical Center","startDate":"2013-11","conditions":"Hepatitis C","enrollment":340},{"nctId":"NCT01466790","phase":"PHASE2","title":"A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-01","conditions":"Hepatitis C","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":87,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sovaldi","Olysio","TMC435"],"phase":"marketed","status":"active","brandName":"Sofosbuvir + Simeprevir","genericName":"Sofosbuvir + Simeprevir","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir and simeprevir work together to inhibit hepatitis C virus replication by blocking the NS5B polymerase and NS3 protease, respectively. Used for Chronic hepatitis C virus infection (genotype 1-6).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}